2-aminoquinoline derivatives

Details 2-aminoquinoline derivatives 2-aminoquinoline derivatives

2011-08-09

2011-08-09

Seaman, D (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S160000

Reexamination Certificate

active

07994324

ABSTRACT:
The present invention is concerned with 2-aminoquinoline derivatives, in particular compounds of formula (I)wherein R1and R2are as described herein, pharmaceutical compositions containing such compounds, and methods for their manufacture. The compounds of the invention are 5-HT5Areceptor antagonists useful in the prevention and/or treatment of depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, dementia, disorders of eating behaviors, sexual dysfunction, sleep disorders, abuse of drugs, motor disorders such as Parkinson's disease, psychiatric disorders or gastrointestinal disorders.

REFERENCES:
patent: 2007/0202924 (2007-08-01), Lai et al.
patent: 2007/0299074 (2007-12-01), Netz et al.
patent: 2008/0146567 (2008-06-01), Kolczewski et al.
patent: 2009/0227628 (2009-09-01), Kolczewski et al.
patent: 0187845 (2001-11-01), None
patent: 03037872 (2003-05-01), None
patent: WO 03/080579 (2003-10-01), None
patent: WO 2004/034985 (2004-04-01), None
patent: WO 2004/080463 (2004-09-01), None
patent: WO 2004/096771 (2004-11-01), None
patent: 2004106305 (2004-12-01), None
patent: WO 2005/082871 (2005-09-01), None
patent: 2006103511 (2006-10-01), None
patent: 2008037626 (2008-04-01), None
patent: WO 2008/068157 (2008-06-01), None
Giordanetto, Bioorg & Med Chem Lett, vol. 17, pp. 4232-4241, 2007.
Hoyer et al., Pharmacol. Rev. vol. 46, pp. 157-204 (1994).
Rees et al., FEBS Lett. vol. 355, pp. 242-246 (1994).
Francken et al., Eur. J. Pharmacol. vol. 361, pp. 299-309 (1998).
Noda et al., J. Neurochem. vol. 84, pp. 222-232 (2003).
Thomas, D. R., Pharmacol. Ther. vol. 111(3) pp. 707-714 (2006).
Doly et al., The Journal of Comparative Neurology vol. 476 pp. 316-329 (2004).
Dubertret et al., J. of Psychiatric Research vol. 35 pp. 371-376 (2004).
Garcia-Ladona et al., 36thAnnual Meeting Soc. Neurosci. Oct. 14-Oct. 18, Atlanta Abstract 33.1 (2006).
Drescher et al., 36thAnnual Meeting Soc. Neurosci. Oct. 14-Oct. 18, Atlanta Abstract 33.2 (2006).
Thomas, Neuropharmacology vol. 51(3) pp. 566-577 (2006).
Barnes et al., Neuropharmacology vol. 38 pp. 1083-1152 (1999).
Pasqualetti et al., Mol. Brain Res. vol. 56 pp. 1-8 (1998).
Wang et al., Neurosci. Lett. vol. 278 pp. 9-12 (2000).
Birkett et al., Neuroreport vol. 11 pp. 2017-2020 (2000).
Iwata et al., Mol. Psychiatry vol. 6 pp. 217-219 (2001).
Duncan et al., Brain Research vol. 869, pp. 178-185 (2000).
Sprouse et al., Synapse, vol. 54(2) pp. 111-118 (2004).
Office Action issued Jul. 1, 2010 in corresponding U.S. Appl. No. 11/946,947, filed Nov. 29, 2007.
Office Action issued Jul. 1, 2010 in corresponding U.S. Appl. No. 12/394,083, filed Feb. 27, 2009.
Office Action issued Aug. 10, 2010 in corresponding U.S. Appl. No. 12/394,083, filed Feb. 27, 2009.
Burkhalter, XP002469319 pp. 4837-4839 (1951).
Database CA Chem. Abstract XP002542080.
Acheson, J. Chem. Soc. pp. 4440-4443 (1955).

Affiliated with

Also associated with

Rating

2-aminoquinoline derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2-aminoquinoline derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-aminoquinoline derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2703367